<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289522</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2008-03 TPEx</org_study_id>
    <secondary_id>2008-004869-25</secondary_id>
    <nct_id>NCT01289522</nct_id>
  </id_info>
  <brief_title>Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer</brief_title>
  <acronym>TPEx</acronym>
  <official_title>Phase II Study of Cetuximab, Docetaxel and Cisplatin as First-line Treatment in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinomas - GORTEC 2008-03 TPEx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE: Cetuximab with platinum and 5FU is now the standard combination as first-line&#xD;
      treatment in patients with metastatic or recurrent Head and Neck squamous cell carcinomas.&#xD;
      Cetuximab and taxane combinations have demonstrated promising activity in Head and Neck&#xD;
      cancer. This phase II trial is studying new cetuximab, docetaxel and cisplatin combination&#xD;
      named TPEx as first-line treatment in this setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the efficacy of TPEx combination in patients with head and neck cancer in&#xD;
           term of objective response rate (RECIST, see statistical consideration) Secondary&#xD;
&#xD;
        -  To assess toxicities of TPEx combination&#xD;
&#xD;
        -  Determine the efficacy of TPEx combination in patients with head and neck cancer: Best&#xD;
           Overall Response , progression-free survival and survival.&#xD;
&#xD;
        -  Translational research objective:To better understand the mechanisms of chemoresistance&#xD;
           and to identify biomarkers by the analysis of the tumor biopsies (RNA, gene expression&#xD;
           profile) and protein profile (plasma samples). Exploratory analyses.&#xD;
&#xD;
      OUTLINE: This is an open-label phase II, multicenter study. Patients receive four cycles of&#xD;
      chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2&#xD;
      hours on day 1. Treatment repeats every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive&#xD;
      a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease&#xD;
      progression or unacceptable toxicities according to the patient or the investigator. Tumor&#xD;
      check-up will be performed every 6 weeks. This study will allow translational research with&#xD;
      blood sample and biopsies at baseline before any treatment, during the treatment with TPEx&#xD;
      combination (week 6).,After completion of study treatment, patients are followed every 2&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Tumor Response Rate</measure>
    <time_frame>12 weeks (after completion of the 4th cycle of chemotherapy)</time_frame>
    <description>The objective tumor response rate is evaluated every 6 weeks according to RECIST criteria.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT-scan or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 1 to 5 Toxicity</measure>
    <time_frame>24 weeks (average)</time_frame>
    <description>All grade 1 to 5 toxicity are registered during treatment. Patients have weekly clinical and biological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Tumor response is evaluated every 6 weeks according to RECIST criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions, Stable Disease (SD); Best overall Response = CR + PR + SD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Squamous Cell Head and Neck Carcinoma</condition>
  <condition>Recurrent or Metastatic Disease</condition>
  <arm_group>
    <arm_group_label>cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab IV</intervention_name>
    <description>Cetuximab 400 mg/m² over 120 minutes on day 1 of cycle 1 only.&#xD;
Cetuximab dose will be 250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.&#xD;
Cetuximab dose will be 500mg/m2 IV every 2 weeks during the maintenance therapy.&#xD;
Drug: Cisplatin IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles&#xD;
Drug: Docetaxel IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles&#xD;
G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy.</description>
    <arm_group_label>cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsies</intervention_name>
    <description>No intervention, only biopsy for translational project.</description>
    <arm_group_label>cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven squamous cell carcinoma of the oral cavity, larynx, oropharynx&#xD;
             or hypopharynx&#xD;
&#xD;
          -  Recurrent disease, incurable disease as determined by surgery or radiation, or&#xD;
             metastatic disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Age &gt; 18 years and &lt;= 70 years&#xD;
&#xD;
          -  WHO performance status 0 or 1&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm3&#xD;
&#xD;
          -  Platelets &gt; 150,000/mm3&#xD;
&#xD;
          -  Total Bilirubin &lt;= institutional upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase &lt; 1.5 X institutional upper limit of normal&#xD;
&#xD;
          -  Alanine aminotransferase &lt; 1.5 X institutional upper limit of normal&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 X institutional upper limit of normal&#xD;
&#xD;
          -  creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Women of child-bearing potential and men must be willing and able practice adequate&#xD;
             contraception prior to study entry and for the duration of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy. Chemotherapy given as part of initial curative therapy and&#xD;
             completed more than 6 months before inclusion is allowed&#xD;
&#xD;
          -  Previous treatment with total doses of cisplatin &gt; 300 mg/ m2&#xD;
&#xD;
          -  Patients must not have any co-existing disease that would preclude cisplatin&#xD;
             administration, such as peripheral neuropathy or renal failure&#xD;
&#xD;
          -  Surgery (excluding biopsy) or radiotherapy within 4 weeks prior to study entry&#xD;
&#xD;
          -  Nasopharyngeal carcinoma, or cancer of sinusal cavities&#xD;
&#xD;
          -  Active infection including tuberculosis or HIV positive patient&#xD;
&#xD;
          -  Other malignancy within last 5 years except for non-melanoma skin cancer&#xD;
&#xD;
          -  No other investigational agent within 30 days prior to study entry&#xD;
&#xD;
          -  No other concurrent chemotherapy, immunotherapy, antitumor hormonal therapy (excluding&#xD;
             contraceptives and replacement steroids), radiotherapy, or experimental medications&#xD;
&#xD;
          -  No prior anti EGFR therapy&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Uncontrolled intercurrent illness that would prevent delivery of protocol therapy&#xD;
&#xD;
          -  Patients with a prior history of basal cell carcinoma of the skin or in situ carcinoma&#xD;
             of the cervix must have been curatively treated and must have remained disease free&#xD;
             for 5 years post diagnosis&#xD;
&#xD;
          -  No history of hypersensitivity reaction to drugs on study&#xD;
&#xD;
          -  No unstable angina or myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No symptomatic congestive heart failure or New York Heart Association (NYHA) class&#xD;
             II-IV heart disease&#xD;
&#xD;
          -  No serious uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  No other prior or concomitant squamous cell carcinoma&#xD;
&#xD;
          -  No other prior or concomitant cancer, except curatively treated basal carcinoma of the&#xD;
             skin or in situ cervical cancer, for which the patient has been curatively treated and&#xD;
             remains disease-free for the past 5 years&#xD;
&#xD;
          -  Patient is pregnant or lactating&#xD;
&#xD;
          -  Patients must not have any co-existing condition that would preclude full compliance&#xD;
             with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel GUIGAY</last_name>
    <role>Study Chair</role>
    <affiliation>GORTEC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique universitaire de Mont Godinne UCL</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin,</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre G-F Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Dracénie</name>
      <address>
        <city>Draguignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <results_first_submitted>February 23, 2017</results_first_submitted>
  <results_first_submitted_qc>February 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2017</results_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous cell carcinoma of the head and neck</keyword>
  <keyword>recurrent or metastatic</keyword>
  <keyword>first line chemotherapy</keyword>
  <keyword>cetuximab</keyword>
  <keyword>docetaxel</keyword>
  <keyword>cisplatin</keyword>
  <keyword>antineoplastic agents</keyword>
  <keyword>First Line Palliative Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cetuximab</title>
          <description>cetuximab IV: - 400 mg/m² over 120 minutes on day 1 of cycle 1 only.&#xD;
250 mg/m² over 60 minutes weekly on subsequent administrations&#xD;
500mg/m2 every 2 weeks during the maintenance therapy. Drug: -Cisplatin IV : 75 mg/m2 every 3 weeks for 4 cycles&#xD;
Docetaxel IV : 75 mg/m2 every 3 weeks for 4 cycles G-CSF support mandatory after each cycle of chemotherapy. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the 4th cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab</title>
          <description>Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according cetuximab IV: - 400 mg/m² over 120 minutes on day 1 of cycle 1 only.&#xD;
250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.&#xD;
500mg/m2 IV every 2 weeks during the maintenance therapy.&#xD;
Drug: Cisplatin IV : 75 mg/m2 every 3 weeks for 4 cycles Drug: Docetaxel IV : 75 mg/m2 every 3 weeks for 4 cycles&#xD;
G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy.&#xD;
Biopsies: No intervention, only biopsy for translational project.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" lower_limit="28.9" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Tumor Response Rate</title>
        <description>The objective tumor response rate is evaluated every 6 weeks according to RECIST criteria.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT-scan or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.</description>
        <time_frame>12 weeks (after completion of the 4th cycle of chemotherapy)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab</title>
            <description>Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according&#xD;
cetuximab IV: - 400 mg/m² over 120 minutes on day 1 of cycle 1 only.&#xD;
250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.&#xD;
500mg/m² IV every 2 weeks during the maintenance therapy. Drug: Cisplatin IV : 75 mg/m² every 3 weeks for 4 cycles Drug: Docetaxel IV : 75 mg/m² every 3 weeks for 4 cycles&#xD;
G-CSF support with lenograstim 150 microg/m²/day is delivered after each cycle of chemotherapy.&#xD;
Biopsies: No intervention, only biopsy for translational project.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response Rate</title>
          <description>The objective tumor response rate is evaluated every 6 weeks according to RECIST criteria.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT-scan or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="30.9" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade 1 to 5 Toxicity</title>
        <description>All grade 1 to 5 toxicity are registered during treatment. Patients have weekly clinical and biological examination.</description>
        <time_frame>24 weeks (average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab</title>
            <description>Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according&#xD;
cetuximab IV: - 400 mg/m² over 120 minutes on day 1 of cycle 1 only.&#xD;
250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.&#xD;
500mg/m² IV every 2 weeks during the maintenance therapy. Drug: Cisplatin IV : 75 mg/m² every 3 weeks for 4 cycles Drug: Docetaxel IV : 75 mg/m² every 3 weeks for 4 cycles&#xD;
G-CSF support with lenograstim 150 microg/m²/day is delivered after each cycle of chemotherapy.&#xD;
Biopsies: No intervention, only biopsy for translational project.</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 1 to 5 Toxicity</title>
          <description>All grade 1 to 5 toxicity are registered during treatment. Patients have weekly clinical and biological examination.</description>
          <units>percentage of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response</title>
        <description>Tumor response is evaluated every 6 weeks according to RECIST criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions, Stable Disease (SD); Best overall Response = CR + PR + SD.</description>
        <time_frame>12 weeks</time_frame>
        <population>2 patients not assessable for response at 12 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab</title>
            <description>Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according&#xD;
cetuximab IV: - 400 mg/m² over 120 minutes on day 1 of cycle 1 only.&#xD;
250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.&#xD;
500mg/m² IV every 2 weeks during the maintenance therapy. Drug: Cisplatin IV : 75 mg/m² every 3 weeks for 4 cycles Drug: Docetaxel IV : 75 mg/m² every 3 weeks for 4 cycles&#xD;
G-CSF support with lenograstim 150 microg/m²/day is delivered after each cycle of chemotherapy.&#xD;
Biopsies: No intervention, only biopsy for translational project.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response</title>
          <description>Tumor response is evaluated every 6 weeks according to RECIST criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions, Stable Disease (SD); Best overall Response = CR + PR + SD.</description>
          <population>2 patients not assessable for response at 12 weeks</population>
          <units>percentage of Best overall ORR</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" lower_limit="39.6" upper_limit="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers</title>
        <time_frame>two years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cetuximab</title>
          <description>Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according cetuximab IV: - 400 mg/m² over 120 minutes on day 1 of cycle 1 only.&#xD;
250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.&#xD;
500mg/m2 IV every 2 weeks during the maintenance therapy.&#xD;
Drug: Cisplatin IV : 75 mg/m2 every 3 weeks for 4 cycles Drug: Docetaxel IV : 75 mg/m2 every 3 weeks for 4 cycles&#xD;
G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy.&#xD;
Biopsies: No intervention, only biopsy for translational project.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>arterial rupture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute alcoholic hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Oral intake reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>oral mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin toxicities</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pr. Joël GUIGAY</name_or_title>
      <organization>Centre Antoine Lacassagne</organization>
      <phone>+33492031000</phone>
      <email>joel.guigay@nice.unicancer.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

